Topics:

ThromboGenics and BioInvent Announce Alliance with Roche

ThromboGenics and BioInvent Announce Alliance with Roche

UVEN, Belgium—ThromboGenics NV and BioInvent International AB (Lund, Sweden) have entered into a license agreement with Roche for their jointly developed anticancer agent TB-403, a novel monoclonal antibody that blocks PIGF, one of the growth factors responsible for angiogenesis.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.